Reata Pharmaceuticals Overview
- Founded
- 2002
- Status
- Public
- Employees
- 349
- Stock Symbol
- RETA
- Share Price
- $27.80
- (As of Thursday Closing)
Reata Pharmaceuticals General Information
Description
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.
Contact Information
Website
www.reatapharma.com
Formerly Known As
Reata Discovery
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 5320 Legacy Drive
- Plano, TX 75024
- United States
+1 (972) 000-0000
Reata Pharmaceuticals Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $27.80 | $26.88 | $20.23 - $153.41 | $1.01B | 36.5M | 671K | -$8.35 |
Reata Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 738,367 | 246,440 | 3,886,366 | 6,592,799 |
| Revenue | 11,459 | 11,490 | 9,019 | 26,517 |
| EBITDA | (252,633) | (243,559) | (235,093) | (284,281) |
| Net Income | (303,773) | (297,386) | (247,752) | (290,170) |
| Total Assets | 679,868 | 735,016 | 857,598 | 682,420 |
| Total Debt | 141,587 | 136,033 | 5,323 | 155,017 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Reata Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Reata Pharmaceuticals‘s full profile, request access.
Request a free trialReata Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore Reata Pharmaceuticals‘s full profile, request access.
Request a free trialReata Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commerci
Biotechnology
Plano, TX
349
As of 2021
00.000
000000000
00.000
00000000
in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat n
0000 000000000
South San Francisco, CA
00
As of 0000
00000
000000000
00000
00000000
scing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veni
0000000000000
Shelton, CT
00
As of 0000
000.00
000000000
000.00
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialReata Pharmaceuticals Competitors (89)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Catalyst Biosciences | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 000000000 | 00000 |
| 0000000000000 | Corporation | Shelton, CT | 00 | 000.00 | 000000000 | 000.00 |
| 0000000 | Venture Capital-Backed | Hannover, Germany | 00 | 00000 | 00000000000 | 00000 |
| 00000000 | Venture Capital-Backed | New Haven, CT | 00 | 00000 | 00000000 | 00000 |
| 000000000 00000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 | 00000 |
Reata Pharmaceuticals Patents
Reata Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210040142-A1 | C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof | Pending | 19-Jul-2019 | 0000000000 | |
| US-20210147380-A1 | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith | Pending | 20-Jun-2018 | 0000000000 | |
| EP-3810141-A1 | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith | Pending | 20-Jun-2018 | 0000000000 | |
| AU-2019286531-A1 | Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma | Pending | 15-Jun-2018 | 0000000000 | |
| CA-3103726-A1 | Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma | Pending | 15-Jun-2018 | C07D231/54 |
Reata Pharmaceuticals Executive Team (19)
Reata Pharmaceuticals Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Jack Nielsen | Self | Board Member | 000 0000 |
| Martin Edwards MD | Self | Board Member | 000 0000 |
| R. Kent McGaughy Jr. | Self | Board Member | 000 0000 |
| Shamim Ruff | Reata Pharmaceuticals | Board Member | 000 0000 |
| William McClellan Jr. | Self | Board Member | 000 0000 |
Reata Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialReata Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Reata Pharmaceuticals‘s full profile, request access.
Request a free trial